Wuxi XDC Placement - Following Biologics Playbook, past Deals Have Been Mixed
WuXi AppTec (2359 HK) aims to raise around US$250m via selling around 3.5% stake in WuXi XDC Cayman (2268 HK). In this note, we talk about the deal...
259 Views
QingSong Health Corporation - Pain Points of the Business Model and the Outlook
By connecting different stakeholders, QingSong can monetize user base. As revenue structure has undergone big changes, it may be hard to generate...
215 Views
Duality Biotherapeutics (映恩生物) Pre-IPO: A Closer Look at Its Core Products
China's Duality Biotherapeutics aims to raise $250m through a Hong Kong listing, with a revised prospectus. In this insight, we took a closer look...
350 Views
Pre-IPO Duality Biotherapeutics (PHIP Updates) - Some Points Worth the Attention
DB-1303 face challenges in commercialization.The priority for DB-1311 is to verify the druggability. Duality’s pre-IPO valuation isn't...
310 Views
Pre-IPO Soft International Group (PHIP Updates) - Some Points Worth the Attention
Soft International faces high competition and slow market growth, with declining performance in 2024. Single-digit net profit margin is...
295 Views